Alaunos Therapeutics, Inc. (NASDAQ:TCRT – Free Report)’s stock is set to reverse split on the morning of Thursday, July 18th. The 1-10 reverse split was announced on Thursday, July 18th. The number of shares owned by shareholders will be adjusted after the market closes on Thursday, July 18th.
Alaunos Therapeutics Stock Down 9.3 %
Shares of TCRT traded down $0.06 during trading hours on Tuesday, reaching $0.61. 197,967 shares of the company traded hands, compared to its average volume of 129,182. The stock’s fifty day moving average is $0.94 and its 200 day moving average is $1.51. Alaunos Therapeutics has a 1-year low of $0.56 and a 1-year high of $7.50.
Alaunos Therapeutics (NASDAQ:TCRT – Get Free Report) last posted its quarterly earnings results on Wednesday, May 15th. The company reported ($0.11) earnings per share (EPS) for the quarter.
Institutional Trading of Alaunos Therapeutics
About Alaunos Therapeutics
Alaunos Therapeutics, Inc, a clinical-stage oncology-focused cell therapy company, develops adoptive T-cell receptor (TCR) engineered T-cell therapies (TCR-T) to treat multiple solid tumor types. It develops Library TCR-T Cell Theraphy, which is in Phase I/II clinical trial for 12 TCRs reactive to mutated KRAS, TP53, and EGFR from its TCR library for the treatment of non-small cell lung, colorectal, endometrial, pancreatic, ovarian, and bile duct cancers.
See Also
- Five stocks we like better than Alaunos Therapeutics
- Insider Buying Explained: What Investors Need to Know
- Tech Leader’s Stock Split: Is It the Right Time to Buy?
- EV Stocks and How to Profit from Them
- Could the Economy be Bottoming? Major Bank’s Earnings Say Yes
- Insider Selling Explained: Can it Inform Your Investing Choices?
- Seize This Prime Stock Opportunity on Amazon Prime Days
Receive News & Ratings for Alaunos Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Alaunos Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.